Medtronic (NYSE:MDT) Q2 2026 Earnings Call November 18, 2025 08:00 AM ET Company ParticipantsVijay Kumar - Senior Managing DirectorThierry Piéton - CFOLaura Mauri - SVP and Chief Scientific and Medical OfficerRyan Weispfenning - Head of Investor RelationsPatrick Wood - Managing DirectorJeff Martha - Chairman and CEOTravis Steed - Managing Director of Equity Research and Medical TechnologyConference Call ParticipantsLawrence Biegelsen - Senior Medical Device Equity Research AnalystPito Chickering - Analyst C ...

Medtronic (NYSE:MDT) Q2 2026 Earnings Call November 18, 2025 08:00 AM ET Company ParticipantsVijay Kumar - Senior Managing DirectorThierry Piéton - CFOLaura Mauri - SVP and Chief Scientific and Medical OfficerRyan Weispfenning - Head of Investor RelationsPatrick Wood - Managing DirectorJeff Martha - Chairman and CEOTravis Steed - Managing Director of Equity Research and Medical TechnologyConference Call ParticipantsLawrence Biegelsen - Senior Medical Device Equity Research AnalystPito Chickering - Analyst C ...

Medtronic (NYSE:MDT) Q2 2026 Earnings Call November 18, 2025 08:00 AM ET Speaker1Hello everyone, and thanks for joining us today for our Fiscal 26 Second Quarter Video Earnings Webcast. I'm Ryan Weispenning, Vice President and Head of Medtronic Investor Relations. Joining me here today are Jeff Martha, Chairman and Chief Executive Officer, and Thierry Piéton, Chief Financial Officer. Jeff and Thierry will provide comments on the results of our second quarter, which ended on October 24, 2025, and our outlook ...

Company Performance - Medtronic reported quarterly earnings of $1.36 per share, exceeding the Zacks Consensus Estimate of $1.31 per share, and up from $1.26 per share a year ago, representing an earnings surprise of +3.82% [1] - The company posted revenues of $8.96 billion for the quarter ended October 2025, surpassing the Zacks Consensus Estimate by 1.11%, compared to $8.4 billion in the same quarter last year [2] - Medtronic has surpassed consensus EPS estimates in all four of the last quarters and topped consensus revenue estimates three times during the same period [2] Stock Performance - Medtronic shares have increased approximately 20.5% since the beginning of the year, outperforming the S&P 500's gain of 13.4% [3] - The current consensus EPS estimate for the upcoming quarter is $1.35 on revenues of $8.83 billion, and for the current fiscal year, it is $5.63 on revenues of $35.8 billion [7] Industry Outlook - The Medical - Products industry, to which Medtronic belongs, is currently ranked in the bottom 30% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of Medtronic's stock may be influenced by the overall outlook for the industry, as research shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Core Insights - Medtronic reported Q2 FY2026 net sales of $8.96 billion, exceeding analyst expectations of $8.87 billion [1] - Adjusted earnings per share were $1.36, higher than the anticipated $1.31 [1] - The cardiovascular segment saw a year-over-year sales increase of 10.8%, reaching $3.44 billion [1] Financial Performance - Q2 FY2026 net sales: $8.96 billion, above expectations [1] - Adjusted EPS: $1.36, surpassing forecasts [1] - Cardiovascular sales: $3.44 billion, up 10.8% year-over-year [1] Future Outlook - The company raised the lower end of its adjusted EPS guidance for FY2026 from $5.60 to $5.62, while maintaining the upper end at $5.66 [1] - Organic revenue growth forecast for the full year increased from approximately 5% to about 5.5% [1]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Financial Performance - Medtronic reported a strong Q2 FY26 with 6.6% reported revenue growth and 5.5% organic revenue growth[17, 22] - Adjusted diluted EPS grew by 8% year-over-year[13, 20] - The company is raising FY26 revenue guidance by 50 bps to 5.5% and EPS guidance to $5.62-$5.66[13] - Adjusted gross margin expanded by 70 bps due to continued COGS efficiency program execution[15, 22] - The company is expecting ~$185 million tariff impact to COGS[54] Segment Performance - Cardiovascular segment showed strong performance with 9.3% organic growth[15, 21] - Cardiac Ablation Solutions (CAS) grew by 71% year-over-year, with 128% US growth[15, 39, 40] - Neuroscience segment grew by 3.9% organically[21] - Diabetes segment grew by 7.1% organically[21] - Medical Surgical segment grew by 1.3% organically[21] Strategic Initiatives - Medtronic is progressing toward Diabetes business separation by the end of CY26, with a preferred path of IPO and split-off[15, 47] - The company is increasing investments in enterprise growth drivers, organic R&D, and sales/marketing[15] - Medtronic is expecting to add incremental $1 billion revenue from Cardiac Ablation Solutions off FY25 base[33] Product and Market Highlights - The company received US FDA approval for Altaviva for treating urge urinary incontinence[15, 28] - Symplicity Spyral received PMDA approval in Japan and US CMS finalized National Coverage Determination[28, 29] - The company is launching new products and driving commercial execution, expecting growth to accelerate in H2 and beyond[15]

Core Insights - Medtronic raised its fiscal-year outlook due to higher profit and sales in its latest quarter [1] - The increase in performance was driven by robust demand across end markets and healthy procedure volumes [1] Financial Performance - The company reported higher profit and sales compared to previous periods [1] - The fiscal-year outlook has been positively adjusted in response to these results [1] Market Demand - There is strong demand across various end markets, contributing to the company's growth [1] - Healthy procedure volumes indicate a positive trend in operational activity [1]

While reporting financial results for the first quarter on Tuesday, medical devices maker Medtronic plc (MDT) raised its adjusted earnings and organic revenue growth guidance for the full-year 2026, given the outperformance in the first half of the year and confidence in revenue growth acceleration.For fiscal 2026, the company now projects adjusted earnings in a range of $5.62 to $5.66 per share on organic revenue growth of about 5.5 percent..Previously, the company expected adjusted earnings in the range ...

Medtronic exceeds fiscal second-quarter earnings and revenue expectations. ...